Neuralink, founded by Elon Musk, has announced a new clinical trial aimed at developing a 'smart bionic eye' to assist individuals with vision loss.
Clinical Trial for Bionic Eye
The trial was added to ClinicalTrials.gov in late July, with sponsorship listed under the University of California at Santa Barbara. The study aims to explore the potential of brain-computer interfaces to restore sight to blind patients using artificial intelligence. Currently, Neuralink patients are not participating in the trials; their involvement is expected 'once available.'
Goals and Plans of Neuralink
This research is part of a broader roadmap targeting the development of the Blindsight chip, designed specifically for vision restoration. Neuralink plans to begin clinical use of the chip by 2030 and expects to achieve $1 billion in annual revenue by 2031. Additionally, two other devices are under development: Telepathy, allowing control of external devices with the mind, and Deep, aimed at treating tremors and Parkinson's disease.
Current Status of Developments
Currently, fewer than ten individuals have received Neuralink implants, none of whom are using the device for blindness or Parkinson’s treatment. These implants have been tested only on paralyzed patients. Neuralink has raised $1.3 billion in investments and is valued at $9 billion, but none of the devices have yet received FDA approval for permanent human use.
Neuralink is actively pursuing new technologies that may transform the treatment of various neurological conditions. However, clear timelines for the use of these devices in humans are not yet established.
